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A B S T R A C T   
Pathological aggregates of alpha-synuclein in peripheral dermal nerve fibers can be detected in patients with 
idiopathic Parkinson’s disease and multiple system atrophy. This study combines skin biopsy staining for p- 
alpha-synuclein depositions and radionuclide imaging of the heart with [123I]-metaiodobenzylguanidine to 
explore peripheral denervation in both diseases. To this purpose, 42 patients with a clinical diagnosis of Par-
kinson’s disease or multiple system atrophy were enrolled. All patients underwent a standardized clinical work- 
up including neurological evaluation, neurography, and blood samples. Skin biopsies were obtained from the 
distal and proximal leg, back, and neck for immunofluorescence double labeling with anti-p-alpha-synuclein and 
anti-PGP9.5. All patients underwent myocardial [123I]-metaiodobenzylguanidine scintigraphy. Dermal p-alpha- 
synuclein was observed in 47.6% of Parkinson’s disease patients and was mainly found in autonomic structures. 
81.0% of multiple system atrophy patients had deposits with most of cases in somatosensory fibers. The [123I]- 
metaiodobenzylguanidine heart-to-mediastinum ratio was lower in Parkinson’s disease than in multiple system 
atrophy patients (1.94 ± 0.63 vs. 2.91 ± 0.96; p < 0.0001). Irrespective of the diagnosis, uptake was lower in 
patients with than without p-alpha-synuclein in autonomic structures (1.42 ± 0.51 vs. 2.74 ± 0.83; p < 0.0001). 
Rare cases of Parkinson’s disease with p-alpha-synuclein in somatosensory fibers and multiple system atrophy 
patients with deposits in autonomic structures or both fiber types presented with clinically overlapping features. 
In conclusion, this study suggests that alpha-synuclein contributes to peripheral neurodegeneration and mediates 
the impairment of cardiac sympathetic neurons in patients with synucleinopathies. Furthermore, it indicates that 
Parkinson’s disease and multiple system atrophy share pathophysiologic mechanisms of peripheral nervous 
system dysfunction with a clinical overlap.   
1. Introduction 
Deposition of alpha-synuclein aggregates in neurons and glia can be 
found in idiopathic Parkinson’s disease (PD) and multiple system atro-
phy (MSA) (Dickson et al., 1999; Dickson et al., 2009). Its accumulation 
is supposed to play a key role in the pathophysiology of both diseases, 
but underlying mechanisms by which alpha-synuclein contributes to 
cellular dysfunction and neuronal cell loss and its pathophysiologic 
spread throughout the nervous system are still not fully understood 
(Borghammer, 2018; Burre et al., 2018; Rocha et al., 2018). In PD, 
alpha-synuclein aggregates are typically found in neurons forming so- 
called Lewy bodies, whereas in MSA oligodendrocytes are predomi-
nantly affected by glial cytoplasmic inclusions (Dickson et al., 1999; 
Dickson et al., 2009; Spillantini, 1999). 
The in vivo demonstration of phosphorylated alpha-synuclein (p- 
alpha-syn) deposits within neurons and neurites outside the central 
nervous system is a recent advancement for histopathological confir-
mation of PD (Donadio et al., 2014; Doppler et al., 2014; Lebouvier 
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et al., 2010; Vilas et al., 2016). Histological specimens of skin are 
particularly easy to obtain, and p-alpha-syn immunoreactivity in dermal 
nerve structures may allow differentiation of PD from tauopathies and 
other forms of parkinsonism (Donadio et al., 2014; Doppler et al., 2014; 
Doppler et al., 2015). Patients with MSA also show p-alpha-syn-positive 
dermal nerve fibers but affected fiber types differ from PD: in MSA, 
depositions have mainly been observed in somatosensory fibers of the 
subepidermal plexus, while they predominantly occur in autonomic 
dermal nerve fibers in PD (Donadio et al., 2018b; Doppler et al., 2015). 
Similarly, differences between the two disorders are known from cardiac 
[123I]-metaiodobenzylguanidine (MIBG) uptake, which is a measure of 
the integrity of postganglionic, presynaptic sympathetic nerve terminals 
of the heart (Orimo et al., 1999). MIBG uptake is typically clearly 
reduced in PD, but not or only slightly reduced in patients with MSA 
(Orimo et al., 2012; Treglia et al., 2012). 
Our study explores the association of dermal p-alpha-syn de-
positions, dermal autonomic denervation, and cardiac denervation in PD 
and MSA patients to disentangle the role of alpha-synuclein in periph-
eral neurodegeneration and to evaluate the diagnostic yield of both 
methods. 
2. Material and methods 
2.1. Patients 
All patients were in- or outpatients at the Department of Neurology, 
University Hospital Würzburg, Würzburg, Germany. Thirty-seven pa-
tients were prospectively enrolled between August 2017 and December 
2018. Data for an additional nine patients originated from prior studies 
examining p-alpha-syn depositions in skin biopsies (Doppler et al., 2014; 
Doppler et al., 2015). All 46 participating subjects underwent a stan-
dardized clinical work-up including neurological examination, nerve 
conduction studies, and blood samples for detection of levels of vitamins 
B12 and B6, methyl malonic acid, and HbA1c. Patients with reduced 
sensory nerve action potential (SNAP) or nerve conduction velocity were 
excluded from assessment of dermal innervation. Hypovitaminoses and 
diabetes mellitus were excluded as potential competing causes of pe-
ripheral nerve impairment. Diagnosis was based on current guideline 
criteria for PD (Postuma et al., 2015) and MSA (Gilman et al., 2008) 
blinded to MIBG scintigraphy results. To additionally assess the strength 
of clinical diagnoses and to identify patients with overlapping features of 
MSA and PD, we evaluated the following criteria for each patient: dis-
ease progression (disease duration (years)/H&Y stage < 2: MSA; > 2: 
PD), autonomic dysfunction (severe: MSA; minor/none: PD), response to 
levodopa (poor: MSA; good: PD), and, if available, [18F]fluorodeox-
yglucose positron emission tomography (hypometabolism of the [pos-
terior] putamen and the cerebellum: MSA; hypermetabolism of the 
striatum or normal striatal uptake: PD) and magnetic resonance imaging 
(putaminal or infratentorial atrophy: MSA; not present: PD) (Krismer 
et al., 2019; Meyer et al., 2017). The number of features for MSA and PD 
were added and resulted in a score for each disease. If the scores differed 
by two or more, the patients were assumed to have PD or MSA with 
typical clinical presentation (tPD, tMSA). In cases where the scores 
differed by less than two, the symptoms were considered as “over-
lapping”, indicating atypical PD or atypical MSA (PD/MSA overlap). 
2.2. Skin biopsy 
5-mm skin punch biopsies were obtained from the distal and prox-
imal leg, back (Th10), and neck (C7) under local anesthesia and cry-
opreserved at − 80 ◦C. 20 μm serial sections were cut as previously 
described (Doppler et al., 2017). Three consecutive 40-μm sections were 
separately cut for assessment of intraepidermal nerve fiber density 
(IENFD). 
2.3. Immunofluorescence labeling 
Double immunofluorescence labeling with mouse anti-p-alpha-syn 
(Biolegend, San Diego, California, USA; 1:500) and rabbit anti-PGP9.5 
(Zytomed Systems, Berlin, Germany; 1:200), rabbit anti-tyrosine hy-
droxylase (TH, Synaptic Systems, Göttingen, Germany; 1:500), or rabbit 
anti-vasoactive intestinal peptide (VIP, Immunostar, Hudson, USA; 
1:1000), and appropriate secondary antibodies (Dianova, Hamburg, 
Germany) was performed as previously described (Doppler et al., 2014). 
Single immunofluorescence labeling of 40-μm sections with anti-PGP9.5 
was done for assessment of IENFD. 
2.4. Microscopy 
IENFD was assessed according to published counting rules (Lauria 
et al., 2005) using a fluorescence microscope (Axiophot 2, Zeiss, Ober-
kochen, Germany) with an Axiocam MRm camera (Zeiss) and SPOT 
software (Diagnostic Instruments, Sterling Heights, Michigan, USA). All 
other slides were evaluated using a fluorescence microscope (Ax10, 
Zeiss) with CARVII system and Visiview software (Visitron GmbH, 
Puchheim, Germany). Innervation of erector pili muscles was quantified 
by taking z stacks (0.5 μm distance). A straight line was drawn 
perpendicularly to the pilomotor nerve fibers at three levels of the 
muscle, crossing nerve fibers per μm were counted, and the mean value 
calculated using ImageJ (National Institutes of Health, Bethesda, 
Maryland, USA) (Schneider et al., 2012). Sweat gland innervation was 
quantified by taking z stacks (0.5 μm distance), obtaining maximum 
projections and calculating the percentage of immunolabeled area per 
sweat gland area using Image J. Due to high background staining and 
autofluorescence of sweat gland vesicles, a different method was applied 
for the quantification of noradrenergic and cholinergic sudomotor 
innervation: the ratio of tubuli per sweat gland, of which the circum-
ference was at least 50%, surrounded by anti-TH− /anti-VIP-immuno-
reactive fibers was calculated. Skin biopsies were classified as p-alpha- 
syn-positive if at least one nerve fiber was p-alpha-syn-immunoreactive. 
For quantification, the ratio of positive biopsy sites per patient (i.e., 
positive biopsy sites/total number of biopsy sites), the number of p- 
alpha-syn-positive structures, and the ratio of p-alpha-syn-positive 
structures divided through the total number of autonomic structures per 
biopsy was calculated. For quantification of p-alpha-syn in anti-TH- and 
anti-VIP-positive fibers, the biopsies with p-alpha-syn within anti-TH− / 
anti-VIP-positive fibers was determined. 
2.5. Nerve conduction studies 
Neurography of the sural nerve was performed using surface elec-
trodes following standard procedures (Kimura, 2013), and was assessed 
based on our normal laboratory values (SNAP ≥ 10 μV for age < 65 
years, amplitude ≥ 5 μV for age ≥ 65 years, nerve conduction velocity >
40 m/s for all ages). 
2.6. MIBG scintigraphy 
Imaging was performed within 30 days after skin biopsy in 77.2% of 
the patients (median 2.5 (range 0–677) d). Medication with known 
interference with MIBG uptake was discontinued prior to imaging as 
recommended by current guidelines (Bombardieri et al., 2010; Flotats 
et al., 2010). MIBG studies were acquired on a dual-headed SPECT/CT 
system (Symbia T2, Siemens Healthineers, Erlangen, Germany), equip-
ped with a medium-energy, low-penetration collimator. Anterior and 
posterior planar images were obtained 240 min after the injection of 
179.5 ± 6.6 MBq MIBG. MIBG uptake was semi-quantitatively assessed 
using the PMOD image analysis software version 3.7 (PMOD Technol-
ogies Ltd., Zurich, Switzerland). First, three experienced nuclear medi-
cine physicians blinded to the clinical information independently 
defined region-of-interests (ROI) of the heart and the mediastinum on 
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the anterior planar images. They manually adjusted a circular ROI to the 
heart and set a rectangular ROI in the upper mediastinum. The heart-to- 
mediastinum (HM) ratio was calculated for each rater by dividing the 
mean counts per pixel in the cardiac ROI by the mean counts per pixel in 
the mediastinal ROI. Finally, mean HM ratios of all three raters were 
calculated. To validate the diagnostic accuracy of MIBG scintigraphy in 
our data, we used a cut-off value of 2.76 for delayed HM ratio, which 
was based on a meta-analysis (Orimo et al., 2012), and converted to a 
camera setting with medium-energy collimators (Brumberg et al., 
2019). 
2.7. Statistical analysis 
Statistical analysis was performed with the commercial software 
package JMP software version 14.0 (SAS Institute Inc., Car, North CA). 
Sample size calculation was based on the primary hypothesis that the 
relative number of p-alpha-syn-positive structures in skin biopsy corre-
lates with HM ratio, and revealed a necessary sample of 45 patients. 
Numerical data were tested for normal distribution using the Shapiro- 
Wilk test. Group comparison between PD and MSA and exploratory 
post hoc group comparison between p-syn-positive and -negative sub-
jects were performed with two-sided Fisher’s exact test, student’s t-test, 
and Mann-Whitney U test as appropriate. Correlations between skin 
biopsy, imaging, and clinical variables were analyzed with a multivar-
iate analysis and Spearman’s ρ over all patients. 2-way full factorial 
analysis of variance was used to test the effect of diagnosis and p-alpha- 
syn deposits in autonomic skin structures on HM ratio. Last, we calcu-
lated sensitivity and specificity for the diagnostic criteria (i) p-alpha- 
syn-positivity in autonomic structures, (ii) p-alpha-syn-negativity in 
somatosensory fibers, and (iii) reduced HM ratio with PD as positive and 
MSA as negative condition. For all analyses, we considered p values <
0.05 as significant. 
2.8. Ethics and protocol approval 
The study was approved by the Institutional Review Board of the 
Julius-Maximilian-University, Würzburg, Germany, and by the 
Governmental Radiation Protection Authority (Bundesamt für Strah-
lenschutz, Salzgitter, Germany, Aktenzeichen: Z5–22463/2–2017-006). 
The study was conducted according to ethical standards in line with the 
Helsinki Declaration of 1975 (and as revised in 1983). All patients gave 
written informed consent to participate. 
3. Results 
3.1. Patients 
Four subjects were excluded because of a final diagnosis of pro-
gressive supranuclear palsy (two patients) or the diagnosis of comor-
bidities within 12 months after MIBG scintigraphy (congestive heart 
failure and peripheral neuropathy, respectively). The remaining 42 pa-
tients had a diagnosis of PD or MSA (21 patients (nine women/12 men) 
in each group). Of the MSA patients, 15 (seven females/eight males) had 
a diagnosis of MSA with predominant parkinsonism (MSA-P) and six 
(two females/four males) had MSA with predominant cerebellar ataxia 
(MSA-C). Gender, age, and disease duration at biopsy did not signifi-
cantly differ between PD and MSA patients. Patients with MSA had a 
more rapid disease progression (p = 0.001), a higher Unified Parkinson’s 
Disease Rating Scale part III score in the medication “on” state (p <
0.001), and a higher score on the non-motor symptom scale (p = 0.04) 
than patients with PD (Table 1). 
3.2. Dermal p-alpha-syn deposition in PD and MSA 
P-alpha-syn deposits were observed in dermal nerve fibers of ten 
patients with PD (47.6%) and 17 patients with MSA (81.0%; MSA-P: 13 
patients, MSA-C: four patients). In PD, p-alpha-syn-positive dermal 
nerve fibers most often innervated autonomic structures such as blood 
vessels, erector pilorum muscles, or sweat glands (six patients, 28.6%). 
In two patients (9.5%), p-alpha-syn deposits were found in somatosen-
sory fibers of the subepidermal plexus, and two patients (9.5%) had 
positive fibers within dermal nerve bundles not attached to a certain 
structure. Patients with MSA predominantly had p-alpha-syn deposits in 
somatosensory fibers (eight patients, 38.1%; MSA-P: six patients, MSA- 
C: two patients), followed by deposits in dermal nerve bundles (five 
patients, 23.8%; MSA-P: three patients, MSA-C: two patients). Two pa-
tients (9.5%, both with MSA-P) showed p-alpha-syn-positivity in auto-
nomic and somatosensory fibers, and in two cases (9.5%, both with 
MSA-P), deposits were observed in autonomic fibers only. In eight PD 
patients with p-alpha-syn-positive fibers (80.0%) and in four of p-syn- 
positive MSA patients (23.5%), deposits were detected in anti-TH- 
immunoreactive fibers. Anti-VIP- and p-syn-positive fibers were detec-
ted in five of p-syn-positive PD patients (50.0%) and in one MSA patient 
(5.9%). The percentage for different types of p-syn-positive autonomic 
structures in relation to total positive autonomic structures was similar 
in PD (skin vessels: 40%, erector pilorum muscles: 40%, sweat glands: 
20%) and MSA (64%, 9%, 27%). P-alpha-syn pathology tended to be 
more frequent (p = 0.05) and was more often located in somatosensory 
fibers (p = 0.01) in MSA compared with PD. No significant differences 
were found between PD and MSA regarding the involvement of auto-
nomic fibers (p = 0.72) (Table 1). Cases with PD had more often p-alpha- 
syn-positive anti-TH-immunoreactive adrenergic fibers (p = 0.01) and 
anti-VIP-immunoreactive cholinergic fibers (p = 0.02) when compared 
to MSA. In p-alpha-syn-positive subjects, the median number of deposits 
(PD: 5 (range 1–16); MSA: 5 (1–37); p = 0.63) and the median per-
centage of positive biopsy sites (PD: 25% (25–67%); MSA: 50% 
(25–100%); p = 0.06) did not differ between groups. P-alpha-syn-posi-
tivity in autonomic structures yielded a sensitivity of 28.6% and a 
Table 1 
Demographic and clinical variables of patients with PD and MSA.   
PD MSA p value 
Gender (females/males) 9/12 9/12 1.000* 
Age at onset (median (range)) 58 (25–73) 61.5 
(43–73) 
0.343# 
Age at biopsy [years] (mean ± SD) 63.3 ± 11.6 64.1 ± 9.0 0.790◦
Disease duration at biopsy (median 
(range)) 
5 (1− 21) 3 (1− 12) 0.062# 
Disease progression (median (range)) 2.5 (0.3–6) 1 (0.25–3.3) 0.001# 
UPDRS total (mean ± SD) 57.0 ± 26.7 91.3 ± 49.5 0.296◦
UPDRS III on (mean ± SD) 26.6 ± 13.1 47.8 ± 10.9 <0.001◦
UPDRS III off (mean ± SD) 38.0 ± 16.2 45.5 ± 12.2 0.363◦
NMS (mean ± SD) 40.3 ± 25.0 98.3 ± 52.4 0.042◦
p-alpha-syn deposits [number of 
patients] (%) 
10 (47.6) 17 (81.0) 0.052* 
p-alpha-syn deposits in autonomic 
structures [number of patients] (%) 
6 (28.6) 4 (19.0) 0.719* 
p-alpha-syn deposits in somatosensory 
fibers [number of patients] (%) 
2 (9.5) 10 (43.5) 0.015* 
p-alpha-syn deposits in dermal nerve 
bundles [number of patients] (%) 
2 (9.5) 5 (23.8) 0.410* 




























HM ratio (mean ± SD) 1.94 ± 0.63 2.91 ± 0.96 <0.001◦
p values are displayed for group comparison by using Fisher’s exact*, Mann- 
Whitney U# and student’s t◦ test. Abbreviations: HM, heart-to-mediastinum 
ratio; IENFD, intraepidermal nerve fiber density; MSA, multiple system atro-
phy; NMS, non-motor symptom scale; p-alpha-syn, phosphorylated alpha- 
synuclein; PD, idiopathic Parkinson’s disease; SD, standard deviation; UPDRS, 
Unified Parkinson’s Disease Rating Scale. 
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specificity of 81.0%, and negative findings for p-alpha-syn in somato-
sensory fibers showed a sensitivity of 90.5% and a specificity of 47.6% to 
separate patients with PD from patients with MSA. 
3.3. Quantification of epidermal and dermal autonomic nerve fibers 
Eight patients had a reduced SNAP or nerve conduction velocity and 
were therefore excluded from this analysis. Quantification of small 
intraepidermal nerve fibers showed a lower median IENFD in biopsies of 
the thigh in PD compared to MSA patients (p = 0.03) (Table1). The 
difference was also significant after correction for gender and age 
(ANCOVA: p = 0.02). The IENFD of the distal leg (ANCOVA: p = 0.15), 
back (ANCOVA: p = 0.12) and neck (ANCOVA: p = 0.60) did not differ 
between groups but tended to be lower in PD compared to MSA. No 
significant differences between groups were found in terms of erector 
pili and sweat gland innervation, or noradrenergic and cholinergic 
sudomotor innervation. Over all patients, IENFD of the distal leg was 
positively correlated with disease duration (ρ = 0.37, p = 0.05), which 
was not significant after correction for age (p = 0.07). 
3.4. Cardiac MIBG scintigraphy differentiates between PD and MSA 
Cardiac MIBG scintigraphy revealed a lower mean HM ratio in PD 
compared to MSA patients (p < 0.001) (Table 1 and Fig. 1). Applying a 
cut-off value of 2.76, 19 of 21 patients with PD and 14 of 21 subjects 
with MSA were concordant with their clinical diagnosis, resulting in a 
sensitivity of 90.5% and a specificity of 66.6% in the study sample. 
3.5. Association of cardiac and dermal autonomic involvement 
Mean HM ratio of patients with p-alpha-syn deposits in autonomic 
structures was significantly lower than of those patients without p- 
alpha-syn-positive autonomic fibers (1.42 ± 0.51 vs. 2.74 ± 0.83; p <
0.0001) (Fig. 1). A reduced HM ratio in patients with proven p-alpha-syn 
pathology in somatosensory fibers (with vs. without: 2.83 ± 1.08 vs. 
2.26 ± 0.86; p = 0.12) or in dermal nerve bundles only (with vs. without: 
2.38 ± 0.97 vs. 2.68 ± 0.90; p = 0.45) was not observed. Of note, this 
was also the case when comparing these groups with p-alpha-syn- 
negative patients only. Multivariate analysis in all patients did not show 
a significant correlation of HM ratio with any other variable, 
particularly not with the absolute or relative number of p-alpha-syn- 
positive structures, the percentage of p-alpha-syn-positive skin biopsy 
sites, or any other marker of dermal innervation. 2-way factorial ANOVA 
revealed that diagnosis (PD vs. MSA; p = 0.007) and p-alpha-syn pa-
thology in autonomic skin elements (p < 0.0001) had an effect with 
regards to the HM ratio but did not have an interaction, indicating that 
the involvement of autonomic structures in skin biopsy had no different 
effect in either patient group. 
3.6. Dermal p-alpha-syn deposition, MIBG scintigraphy, and diagnostic 
categories of different strength 
Thirty patients had a typical clinical presentation (16 tPD, 14 tMSA), 
whereas 12 patients (five PD, seven MSA) had ambiguous clinical fea-
tures and were referred to the PD/MSA overlap group. None of the pa-
tients with tPD had p-alpha-syn deposits in somatosensory fibers, and 
none of the patients with tMSA had p-alpha-syn-positive autonomic 
structures, revealing a negative predictive value of 100% for these pa-
tient groups. The two patients who had p-alpha-syn in both fiber types 
belonged to the PD/MSA overlap group. The mean MIBG HM ratio was 
lower in the PD and PD/MSA overlap groups compared to MSA patients 
(p < 0.001). Concordant results were found in 16 patients (i.e., patho-
logical HM ratio and p-alpha-syn in autonomic fibers [four tPD, three 
PD/MSA overlap], normal HM ratio with p-alpha-syn in somatosensory 
fibers [five tMSA, two PD/MSA overlap], or pathological HM ratio and 
p-alpha-syn in both fiber types [two PD/MSA overlap) (Fig. 2), discor-
dant findings in only four patients (one PD/MSA overlap with normal 
HM ratio and p-alpha-syn in autonomic fibers, one PD/MSA overlap 
with pathological HM ratio and p-alpha-syn in somatosensory fibers, 
two tMSA with pathological HM ratio and p-alpha-syn in somatosensory 
fibers) (Table 2). 
4. Discussion 
We aimed to investigate the association of dermal p-alpha-syn de-
positions and cardiac denervation in patients with PD and MSA. Our 
main finding is that p-alpha-syn depositions in peripheral autonomic 
nerve fibers are associated with sympathetic cardiac denervation, 
whereas p-alpha-syn pathology in somatosensory fibers or dermal nerve 
bundles was not related to decreased cardiac innervation. Accordingly, 
Fig. 1. Boxplots of delayed heart-to-mediastinum (HM) ratio of MIBG scintigraphy. 
Left panel shows the comparison of patients with Parkinson’s disease (PD) and multiple system atrophy (MSA). The middle shows patients without vs. with proof of 
phosphorylated alpha-synuclein (p-alpha-syn) depositions in dermal nerve fibers. On the right side, patients, who were negative for p-alpha-syn in autonomic skin 
elements are compared with positive patients. Patients with PD are represented by squares, circles display patients with MSA. Open squares and open circles indicate 
patients with overlapping clinical symptoms (PD/MSA overlap). * p < 0.0001, two-sample t-test. Abbreviations: MIBG = [123I]-metaiodobenzylguanidine. 
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p-alpha-syn deposition in autonomic fibers and cardiac sympathetic 
denervation in MIBG scintigraphy were mainly found in PD, while p- 
alpha-syn deposition in somatosensory fibers and preserved cardiac 
sympathetic innervation were mostly in MSA. However, discordant 
findings could be found in some patients and were associated with 
clinical overlapping/discordant features in PD and MSA. 
The coincidence of autonomic alpha-synuclein pathology in the skin 
and cardiac denervation suggests that alpha-synuclein affects cardiac 
sympathetic neurons and contributes to neuronal cell loss in these pa-
tients. In fact, prior studies identified alpha-synuclein-positive neurites 
and Lewy bodies in neurons within the heart of patients with PD (Iwa-
naga et al., 1999; Okada et al., 2004), possibly causing degeneration of 
cardiac sympathetic nerves early in the disease course (Orimo et al., 
2008). Our data demonstrate that autonomic denervation and p-alpha- 
syn deposition is associated with the clinical picture of idiopathic PD, 
supporting the diagnostic value of both methods. However, in contrast 
to some recent studies (Donadio et al., 2014; Donadio et al., 2017), we 
did not find a reduction in sweat gland or erector pilorum muscle 
innervation associated with p-alpha-syn deposition in autonomic nerve 
fibers. We therefore cannot give a conclusion on the effect of p-alpha-syn 
deposits on dermal sympathetic denervation. A reason could be that p- 
alpha-syn was mostly found in vasomotor fibers rather than sudomotor 
or pilomotor fibers, and sweat gland and erector pilorum muscle 
innervation may therefore not be significantly affected in our cohort. 
The sensitivity (90.5%) of MIBG scintigraphy for PD in this study was 
expectedly high, whereas specificity (66.6%) was slightly lower but 
within the 95% confidence interval (CI) of a recent meta-analysis 
(sensitivity: 90.2% (CI 84.4–93.9%); specificity: 81.9% (CI 
56.1–94.1%)) (Orimo et al., 2012). Likewise, fiber-type involvement 
differed between PD and MSA but was not 100% specific for both groups 
as previously reported (Doppler et al., 2015). However, sensitivity and 
specificity to separate PD from MSA by using either p-alpha-syn deposits 
in autonomic structures (28.6% and 81.0%) or negativity for p-alpha- 
syn in somatosensory fibers (90.5% and 47.6%) as diagnostic criteria are 
below published values. Recent studies reported 92.3% specificity for 
autonomic p-alpha-syn deposits (Giannoccaro et al., 2020) and 72.0% 
specificity for p-alpha-syn-negativity in somatosensory fibers (Donadio 
et al., 2020) (note that this reference defined MSA as positive condition 
and evaluated the diagnostic criterion “p-alpha-syn-positivity in so-
matosensory fibers” why the values for sensitivity and specificity were 
adjusted to meet the present definition of positive [PD] and negative 
cases [MSA]). The discrepancies might be related to the selection of 
included patients, since the reported values of 97.5–100.0% sensitivity 
and 100.0% specificity for MIBG scintigraphy (Donadio et al., 2020; 
Giannoccaro et al., 2020) do not reflect clinical reality and exceed the 
diagnostic accuracy of this method (Orimo et al., 2012). In our study, the 
clinical diagnosis was blinded to the results of MIBG scintigraphy and 
relied on clinical guideline criteria only (Gilman et al., 2008; Postuma 
et al., 2015) preventing the identification of patients with inconclusive 
pathology of the peripheral nervous system before study inclusion, and 
thus a possible selection bias. Of relevance, specificity of both methods 
was much higher in our study when patients with overlapping features 
were excluded, suggesting that these patients must be considered 
separately from patients with typical clinical presentation. Involvement 
of autonomic or somatosensory nerve fibers in p-alpha-syn deposition, 
Fig. 2. Photomicrographs of double-immunofluorescence staining with anti-p-syn (red) and anti-PGP9.5 (green), and MIBG scintigraphy. 
P-alpha-syn depositions in autonomic structures, such as blood vessels, were associated with a reduced cardiac HM ratio (A). Patients with deposits in somatosensory 
fibers of the subepidermal plexus predominantly showed a normal cardiac innervation (B). Cell nuclei are stained with DAPI (blue). Scale bar = 20 μm; gradient bar is 
scaled to minimal and maximal MIBG uptake. Abbreviations: MIBG = [123I]-metaiodobenzylguanidine. 
Table 2 




Gender (females/males) 6 /10 5/7 7/7 
p-alpha-syn deposits [number of patients] 
(%) 
6 (37.5) 9 (75.0) 12 (85.7) 
p-alpha-syn deposits in autonomic 
structures [number of patients] (%) 
4 (25.0) 6 (50.0) 0 (0.0) 
p-alpha-syn deposits in somatosensory 
fibers [number of patients] (%) 
0 (0.0) 5 (41.7) 7 (50.0) 
p-alpha-syn deposits in dermal nerve 
bundles [number of patients] (%) 
2 (12.5) 0 (0.0) 5 (35.7) 
HM ratio (mean ± SD) 1.96 ±
0.64 
2.17 ± 1.00 3.18 ±
0.76 
Pathological HM ratio [number of 
patients] (%) 
15 (93.8) 7 (58.3) 4 (28.6) 
Normal HM ratio [number of patients] (%) 1 (16.2) 5 (41.7) 10 (71.4) 
Concordance MIBG scintigraphy & skin 
biopsy [number of patients] (%) 
4 (100.0 
a) 
7 (77.8 a) 5 (71.4 a) 
Discordance MIBG scintigraphy & skin 
biopsy [number of patients] (%) 
0 (0.0 a) 2 (22.2 a) 2 (28.6 a)  
a Denominator refers to number of patients with p-alpha-sun deposits in 
autonomic and/or somatosensory fibers. Abbreviations: HM, heart-to- 
mediastinum; MIBG, [123I]-metaiodobenzylguanidine; p-alpha-syn, phosphory-
lated alpha-synuclein; PD/MSA overlap, PD and MSA patients with overlapping 
symptoms; SD, standard deviation; tMSA, multiple system atrophy with typical 
clinical presentation; tPD, Parkinson’s disease with typical clinical presentation. 
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however, may contribute to the differential diagnosis in patients with 
overlapping features and may be combined with neuroimaging to in-
crease the diagnostic confidence. Seven patients with concordant find-
ings belonged to the PD/MSA overlap group, suggesting that the 
combination of skin biopsy and MIBG scintigraphy can improve diag-
nostic confidence in these patients. 
Four patients showed inconclusive findings, of which two were 
assigned to the PD/MSA overlap group. Remarkably, two more patients 
in this group had the combination of p-alpha-syn deposition in auto-
nomic and somatosensory fibers. This indicates that mechanisms of both 
peripheral autonomic degeneration and somatosensory involvement 
may occur to some extent in both diseases or in a clinically indefinite 
patient cluster, supporting the idea of the existence of overlapping 
syndromes. The latter has been suggested before, based on overlapping 
clinical features (Krismer et al., 2014), potential impairment of cardiac 
innervation in both diseases (Nagayama et al., 2010), and histopatho-
logical findings (i.e., alpha-synuclein-related pathology in thoracic 
sympathetic ganglia in patients with advanced MSA) (Sone et al., 2005). 
Either peripheral autonomic degeneration or somatosensory involve-
ment in the majority of patients, and coincidence of autonomic and 
somatosensory involvement in single patients, supports the concept that 
deposition of p-alpha-syn in specific cell types may be facilitated by a 
selective cell or neuronal vulnerability related to the genetic profile of 
patients (Walsh and Selkoe, 2016). We speculate that such a profile 
might determinate peripheral nervous system involvement, and its 
expression is more frequent in either PD or MSA but does not represent 
an exclusive feature for the respective entity. Remarkably, the HM ratio 
was lower in PD patients with than without dermal p-alpha-syn depo-
sition, suggesting different extents of affection of autonomic nerves 
within the PD group. 
Two PD patients and five patients with MSA had p-alpha-syn deposits 
in dermal nerve bundles, which may include both autonomic and so-
matosensory fibers. We reviewed their anti-TH- and anti-VIP- 
immunoreactivity to clarify if these fibers might be autonomic: p- 
alpha-syn-positive fibers of one PD patient (with pathologic HM ratio) 
were also anti-TH-positive, whereas p-alpha-syn deposits of all other 
subjects were negative for both autonomic markers. This observation is 
in line with the overall results of the study, however, we did not consider 
anti-TH-positivity as confirmatory for autonomic involvement in this 
case, since preclinical evidence indicates that some sensory fibers of the 
skin may show anti-TH-immunoreactivity (Brumovsky et al., 2006) – 
and vice-versa, the lack of anti-TH- and anti-VIP-positivity does not 
prove that these fibers are actual somatosensory. 
The overall detection rate of dermal p-alpha-syn depositions match 
previous findings, although detection of p-alpha-syn in 47.6% of PD 
patients in our study was below the reported range of 51.6–100% 
(Donadio et al., 2014; Donadio et al., 2018a; Doppler et al., 2014; 
Doppler et al., 2017; Zange et al., 2015). One possible explanation for 
the low rate could be that we did not exclude subjects with early disease 
onset, who have more likely PD gene mutations (Blauwendraat et al., 
2020), while the presence of dermal p-alpha-syn deposits in different 
forms of monogenic PD is still subject to current research (Doppler et al., 
2018). Out of three patients with early onset PD, two were tested 
negative for PRKN and LRRK2 mutations (one with p-alpha-syn in so-
matosensory fibers, one without p-alpha-syn deposits), whereas no ge-
netic testing was performed in the remaining patient (p-alpha-syn- 
negative). Although compound heterozygosity for the PRKN gene causes 
up to 50.0% of early onset PD (Jankovic and Tan, 2020), other muta-
tions related to early onset PD, and thus, a possible effect on positivity 
rate cannot be excluded. The percentage of MSA patients with dermal p- 
alpha-syn pathology in our sample (81.0%) was slightly higher than 
previously observed (66.6%) (Donadio et al., 2018b; Doppler et al., 
2015), mainly driven by the high detection rate in patients with MSA-P. 
As could be assumed from the clinical profile, no subjects with MSA and 
predominant cerebellar ataxia had p-alpha-syn deposits in autonomic 
skin elements, but 33.3% had deposits in somatosensory fibers; this 
indicates the involvement of the peripheral nervous system in both MSA 
subtypes, with more clinical as well as histopathological similarities 
between MSA-P and PD. However, due to the small sample size, final 
conclusions cannot be drawn on this subgroup. 
This study has several limitations. First, the sensitivity of skin biopsy 
is limited, most probably because p-alpha-syn-positive fibers are rare 
and do not occur in all skin sections. Second, reduced cardiac MIBG 
uptake can be related to alpha-synuclein aggregation (Iwanaga et al., 
1999; Okada et al., 2004; Orimo et al., 2008), but is an unspecific 
measure that does not prove Lewy body disease and particularly not 
alpha-synuclein pathology. It may also be caused by (occult) congestive 
heart failure, ischemic heart disease, or neuropathy (Henzlova et al., 
2016; Jacobson et al., 2010). This was the case in two subjects with MSA 
in our study sample, who therefore had to be excluded. Third, the 
clinical diagnosis as reference standard is limited in parkinsonian syn-
dromes, since it is not confirmed by autoptic findings in up to 20% of 
patients (Hughes et al., 2002; Litvan et al., 1997). Future studies on this 
topic with histopathological post-mortem confirmation are therefore 
warranted. 
5. Conclusions 
This study provides evidence that alpha-synuclein engages periph-
eral neurodegeneration and mediates the impairment of cardiac sym-
pathetic neurons in patients with synucleinopathies. Furthermore, it 
indicates that PD and MSA share pathophysiologic mechanisms of pe-
ripheral nervous system dysfunction with a clinical and peripheral his-
topathological overlap. 
Funding 
This study was sponsored by the Interdisziplinäres Zentrum für kli-
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